studies

lung cancer : non small cell (NSCLC), ... vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsTORCH, 2008 1.24 [1.04; 1.47] 1.24[1.04; 1.47]TORCH, 200810%760NAnot evaluable progression or deaths (PFS)detailed resultsTORCH, 2008 1.21 [1.04; 1.41] 1.21[1.04; 1.41]TORCH, 200810%760NAnot evaluable objective responses (ORR)detailed resultsTORCH, 2008 0.52 [0.38; 0.73] 0.52[0.38; 0.73]TORCH, 200810%760NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-10-03 09:12 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334 - treatments: 976

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons